c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Products of "c-Met/HGFR"
Sort by
Golvatinib
CAS:Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFormula:C33H37F2N7O4Purity:98.24% - ≥95%Color and Shape:SolidMolecular weight:633.69MK-8033
CAS:MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Formula:C25H21N5O3SPurity:97.16%Color and Shape:SolidMolecular weight:471.53MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Formula:C26H23N7OPurity:98%Color and Shape:SolidMolecular weight:449.51Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Formula:C31H29FN4O5Purity:99.77% - 99.95%Color and Shape:SolidMolecular weight:556.58PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Formula:C32H34Cl2N4O4SPurity:97.01% - 99.35%Color and Shape:SolidMolecular weight:641.61MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Formula:C26H20FN5O2S2Purity:98.06% - 98.68%Color and Shape:SolidMolecular weight:517.6AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Formula:C22H17N5O2Purity:98.56%Color and Shape:SolidMolecular weight:383.4Tepotinib hydrochloride(1 : x)
CAS:Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14Formula:C29H29ClN6O2Purity:99.81%Color and Shape:SolidMolecular weight:529.04Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Formula:C23H19Cl2FN6OPurity:98.80%Color and Shape:SolidMolecular weight:485.34Ref: TM-T4260
1mg44.00€2mg55.00€5mg70.00€10mg87.00€25mg145.00€50mg258.00€100mg430.00€500mg998.00€1mL*10mM (DMSO)97.00€c-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formula:C17H14N8SPurity:98.77%Color and Shape:SolidMolecular weight:362.41Ref: TM-T10655
1mg85.00€5mg172.00€10mg236.00€25mg398.00€50mg588.00€100mg838.00€1mL*10mM (DMSO)188.00€Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H17FN6OPurity:99.24%Color and Shape:SolidMolecular weight:412.42Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Formula:C23H21Cl2FN6O2Purity:99.77%Color and Shape:SolidMolecular weight:503.36Ref: TM-T8825
2mg35.00€5mg49.00€10mg69.00€25mg115.00€50mg177.00€100mg283.00€200mg378.00€1mL*10mM (DMSO)56.00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Formula:C34H34F2N4O6Purity:98.07% - 99.68%Color and Shape:SolidMolecular weight:632.65Ref: TM-T3113
2mg39.00€5mg57.00€10mg79.00€25mg133.00€50mg207.00€100mg354.00€500mg848.00€1mL*10mM (DMSO)79.00€Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Formula:C34H29ClF2N6O5Purity:98%Color and Shape:SolidMolecular weight:675.08Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formula:C27H23FN4O4SPurity:99.39%Color and Shape:SolidMolecular weight:518.56Ref: TM-T13108
1mg50.00€5mg106.00€10mg158.00€25mg258.00€50mg379.00€100mg538.00€200mg733.00€1mL*10mM (DMSO)134.00€JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formula:C20H12F2N6Purity:98.84% - 99.52%Color and Shape:SolidMolecular weight:374.35Ref: TM-T15617
1mg63.00€2mg89.00€5mg137.00€10mg210.00€25mg424.00€50mg627.00€100mg893.00€500mg1,786.00€1mL*10mM (DMSO)153.00€Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Purity:SDS-PAGE:95% SEC-HPLC:97.51%Color and Shape:LiquidMolecular weight:145.2 kDaAltiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Formula:C26H21F3N4O4Purity:98.98% - 99.39%Color and Shape:SolidMolecular weight:510.46BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFormula:C17H15N5Purity:98.98%Color and Shape:SolidMolecular weight:289.33Ref: TM-T7900
1mg50.00€5mg97.00€10mg170.00€25mg306.00€50mg444.00€100mg620.00€200mg835.00€1mL*10mM (DMSO)114.00€
